A Systems Biology-Based Approach to Uncovering the Molecular Mechanisms Underlying the Effects of Dragon’s Blood Tablet in Colitis, Involving the Integration of Chemical Analysis, ADME Prediction, and Network Pharmacology

Haiyu Xu 1,2*, Yanqiong Zhang 1*, Yunlei 1,3*, Xiumei Gao 1,4, Huaiqiang Zhai 3, Na Lin 1, Shihuan Tang 1, Rixin Liang 1, Yan Ma 1, Defeng Li 1, Yi Zhang 1, Guangrong Zhu 5, Hongjun Yang 1*, Luqi Huang 2*

1 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, P.R. China, 2 National resource center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, P.R. China, 3 Beijing University of Chinese Medicine, Beijing, P.R. China, 4 Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China, 5 Yunnan Datang Hanfang Pharmacy co.ltd, Yunnan, P.R. China

Abstract

Traditional Chinese medicine (TCM) is one of the oldest East Asian medical systems. The present study adopted a systems biology-based approach to provide new insights relating to the active constituents and molecular mechanisms underlying the effects of dragon’s blood (DB) tablets for the treatment of colitis. This study integrated chemical analysis, prediction of absorption, distribution, metabolism, and excretion (ADME), and network pharmacology. Firstly, a rapid, reliable, and accurate ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry method was employed to identify 48 components of DB tablets. In silico prediction of the passive absorption of these compounds, based on Caco-2 cell permeability, and their P450 metabolism enabled the identification of 22 potentially absorbed components and 8 metabolites. Finally, networks were constructed to analyze interactions between these DB components/metabolites absorbed and their putative targets, and between the putative DB targets and known therapeutic targets for colitis. This study provided a great opportunity to deepen the understanding of the complex pharmacological mechanisms underlying the effects of DB in colitis treatment.

Introduction

Traditional Chinese medicine (TCM) is one of the oldest medical systems of health care, and it has been used in East Asian countries such as China, Japan, and Korea for thousands of years [1,2]. However, acceptance of traditional Chinese medicines within Western biomedical practice has been restricted by a lack of knowledge of the active compounds involved, and their therapeutic mechanisms of action [3]. TCM is characterized by the usage of multi-component, multi-target agents that collectively modulate molecular networks. Recently, network pharmacology has provided a means to improve understanding of the molecular mechanisms underlying the therapeutic effects of traditional Chinese medicines [3–5]. TCM chemical databases such as TCM Database@Taiwan [6] and HerbBioMap database [7] and some literature generally provide the main sources of information on the chemical profiles of traditional Chinese medicines. However, these are not always accurate because the chemical profiles of traditional Chinese medicines can vary significantly, depending on the geographical origin of the materials used, the harvest time, pretreatments, and manufacturing processes employed. In addition, most TCM formulations are taken orally, estimation of intestinal absorption and cytochrome P450 metabolism provide more in-depth insights into their therapeutic
Uncovering the Molecular Mechanisms of DB in Colitis Systemically

---

**Step 1 Chemical analysis**

Dragon’s blood tablet (DBT) → Prototype compounds of DBT

---

**Step 2 ADME prediction**

Prototype absorbed compounds of DBT → Predicting metabolites based on P450 regioselectivity module → Predicted metabolites

---

**Step 3 Network pharmacology**

Chemical database of DB → Known drugs of high similarity with compounds in DB → Targets for known drugs → DrugBank

---

Putative targets for DB → known therapeutic targets of colitis

---

Chemical component-putative target network → Putative targets of DB-known therapeutic targets of colitis network

---

Network analysis → Pharmacological mechanisms of DB
mechanisms [8,9]. However, experimental determination using these systems can be costly and time-consuming. To obtain a rapid estimation of human absorption and metabolism, high throughput screening methods using Caco-2 cell monolayers and P450 enzymes provide the most advanced in vitro approaches to assessing new chemical entities [10–12]. Thus, the development of rapid high-throughput approaches to studying TCM compositions and mechanisms, combining chemical analysis, prediction of absorption, distribution, metabolism, and excretion (ADME), and network pharmacology is required.

According to the Pharmacopoeia of the People’s Republic of China, commercially available longxuejie or dragon’s blood (DB) includes plant resins from four species; Dracaena spp., Daemonorops spp., Croton spp., and Pterocarpus spp., and has long been used as an ethnomedicine in China to invigorate blood circulation in the treatment of traumatic injuries, blood stasis, and pain [13,14]. DB has also been used to treat chronic colitis in recent decades and many clinical studies have reported good therapeutic effects [15–17]. Chemically, flavonoids, phenols, steroids, and terpenoids have been identified as the main constituents of DB [18–22]. Some analytical methods have been developed to identify and characterize DB composition and assess its quality [23–25]. Pharmacologic studies of these components have identified a wide variety of actions, including anti-inflammatory, antiulcer, antimicrobial, hemostatic, and analgesic activities, which could contribute to their efficacy in the treatment of chronic colitis [26–28]. However, the precise active constituents of DB that have benefits in chronic colitis, and their molecular mechanisms of action, are still unclear. In particular, the lack of elucidation of the ingredient-target network has hindered understanding of the molecular mechanisms of DB in chronic colitis treatment.

The present study employed high-throughput analysis, in silico ADME models, and a network pharmacology technique to investigate the active constituents of DB and their actions on molecular networks in chronic colitis, as shown in Figure 1.

Materials and Methods

1. Reagents and chemicals

High performance liquid chromatography (HPLC)-grade acetoneitrile, formic acid, and methanol were obtained from Merck (Darmstadt, Germany). Water was purified using a Milli-Q system (Millipore, Billerica, MA, USA). 7,4′-Dihydroxyflavan, loureirin A, loureirin B, dracaenin A and pterostilbene standards were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). The purities of all standards were no less than 98% and suitable for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. DB enteric-coated tablets were supplied from Yunnan Datang Hanfang Pharmaceutical Co. Ltd. (Yunnan, China).

2. Preparation of samples and standard solution

Six different batches of DB enteric-coated tablets were pulverized with a 60 mesh, respectively. Each sample of this powder (0.1 g) was weighed precisely and ultrasonically extracted in 10 ml methanol for 20 min at room temperature. The solution was centrifuged at 12000 rpm for 10 min, and then filtered through 0.22 μm nylon membrane filters. The filtrate was analyzed directly by UPLC-ESI-MS/MS, as described in section 2.3. At the same time, a stock solution containing five standards (7,4′-dihydroxyflavan, loureirin A, loureirin B, pterostilbene, and dracaenin A) was prepared in methanol. All solutions were stored at 4°C prior to analysis.

3. Instrument and UPLC-ESI-MS/MS conditions

UPLC was performed on a Dionex UltiMate 3000 system (Dionex Corporation, Sunnyvale, USA) equipped with a quaternary pump, an online vacuum degasser, an autosampler, and an automatic thermostatic column oven. A Thermo Hyper Gold C18 column was used (100×2.1 mm, 1.9 μm) at 30°C with a flow rate of 0.4 ml/min and an injection volume of 5 μl. The mobile phase was a mixture of 0.1% formic acid in water (A) and acetonitrile (B). The mobile phase gradient program was 5% B, 0–3 min; 5–95% B, 3–20 min; 95% B, 20–25 min. High-resolution accurate-mass full scan LC-MS and LC-MS/MS analyses were performed using Thermo Q-Exactive (Thermo Fisher Scientific, Bremen, Germany). Full scans were acquired in the mass analyzer at 100–1500 m/z with a resolution of 70000 in both positive and negative ion modes, and MS/MS scans were obtained with a resolution of 17500 using a normalized collision energy of 30% for high-energy collisional dissociation fragmentation. Based on the best response for most compounds, the final parameters were set as follows: spray voltage, 3.2 kV in the positive mode and 3.0 kV in the negative mode; capillary temperature, 350°C; sheath gas pressure, 35 arbitrary units; auxiliary gas pressure, 10 arbitrary units; and heater temperature, 300°C. Xcalibur 2.2 software (Thermo Fisher Scientific) was used for data acquisition.

4. Prediction of absorbed constituents and their metabolites using in silico ADME models

Structural information (*.mol or *.sdf files) relating to the DB components (identified by UPLC-ESI-MS/MS) were downloaded from ChemSpider (http://www.chemspider.com/). ADME evaluation of these constituents was carried out using ACD/Percepta software 5.07 (ACD/Labs, Toronto, Canada), including the passive intestinal permeability of Caco-2 module and the P450 regioselectivity module to predict their oral bioavailability. The apparent permeability coefficient (Papp) of one constituent was greater than 9.0×10^-6 cm/s, which indicated good absorption characteristics. The score and the reliability of metabolic reaction were set at greater than 0.6 and 0.5, respectively, in order to increase prediction credibility.

5. Known therapeutic targets for colitis treatment

Known therapeutic targets were obtained from the DrugBank database [29] (http://www.drugbank.ca/, version: 3.0). We only included drug-target interactions where the drugs were approved by the Food and Drug Administration, USA (FDA) for the treatment of colitis, with human gene/protein targets. To facilitate data analysis, all protein identification codes were converted to a common UniProtKB-Swiss-Prot code, and detailed target information is provided in the supplementary Table S1.

6. PPI data collection

PPI data were imported from eight existing PPI databases, including the Human Annotated and Predicted Protein Interaction Database (HAPPi) [30], Reactome [31], Online Predicted Human Interaction Database (OPHID) [32], InAct [33], Human Protein Reference Database (HPRD) [34], Molecular Interaction...
Database (MINT) [35], Database of Interacting Proteins (DIP) [36], and PDZBase [37]. Detailed information on these PPI databases is provided in the supplementary Table S2.

7. Pharmacological mechanism analysis

7.1. Prediction of putative DB targets. As described in our previous study [38], we used the Drug Similarity Search tool in the Therapeutic Targets Database [39] (TTD, http://xin.cz3.nus.edu.sg/group/cjttd/ttd.asp, Version 4.3.02, released on Aug 25th 2011) to screen drugs similar to DB via structural similarity comparisons. We only selected drugs with a high structural similarity score (>0.85, similar to very similar) with the potentially absorbed DB constituents and their metabolites. The therapeutic targets of these similar drugs were also included as putative DB targets.

7.2. Network construction and analysis. The absorbed DB components and their metabolites, their putative targets, and known therapeutic targets for colitis treatment were used to construct a chemical component-putative target network, and a putative DB targets-known colitis therapeutic targets PPI network, respectively. PPI data were obtained from eight existing PPI databases, as described in section 2.6. Navigator software (Version 2.2.1) and Cytoscape (Version 2.8.1) were utilized to visualize the networks.

For each node “i” in these two networks, we defined four measures of topology: (1) “degree,” defined as the number of links to node i; (2) “betweenness,” defined as the capacity of node i to be located in the shortest communication paths between different pairs of nodes in the network [40]. The betweenness centrality of node i is computed as following formula:

\[
B(i) = \frac{\sum_{s \neq i \neq t} \left( \frac{\sigma_{st}(i)}{\sigma_{st}} \right)}{(N-1)(N-2)/2}
\]

where \( \sigma_{st} \) denotes the number of the shortest paths between node s and node t in the PPI network, \( \sigma_{st}(i) \) denotes the number of the shortest paths across node i between node s and node t, and N is the total number of nodes in the PPI network. This property correlates more closely with essentiality than connectivity, exposing critical nodes that usually belong to the group of scaffold proteins or proteins involved in crosstalk between signal pathways (called bottlenecks) [41]. (3) “closeness,” defined as the inverse of the sum of node i distances to all other nodes. Closeness can be regarded as a measure of how long it would take to spread information from node i to all other nodes sequentially. Degree, betweenness and closeness centralities correlate with a protein’s topological importance in the PPI network [40]. (4) K-core analysis is an iterative process in which nodes were removed from the network in order of the least-connected [42]. The core of maximum order is defined as the main (highest) k-core in the network. A k-core sub-network of the original network can be generated by recursively deleting vertices from the network whose degree is less than k. This results in a series of sub-networks that gradually reveal the globally central region of the original network. On this basis, “k value” is used to measure the centrality of node i.
Table 1. MS data of ESI-MS spectra and identification of the Longxuejie enteric-coated tablet.

| No. | RT (Measured) | m/z (Measured) | m/z (Expected) | m/z (Delta, ppm) | polarity | Formula | Compound Name | Papp (10⁻⁶ cm/s) |
|-----|---------------|----------------|----------------|------------------|----------|---------|---------------|-----------------|
| 1   | 8.11          | 311.11395      | 311.11363      | 1.046            | negative | C₇H₉O₇   | 3,4-dihydroxyallylbenzene 4-O-D-Glucopyranoside | 3.8494          |
| 2   | 8.38          | 285.07592      | 285.07575      | 0.594            | positive  | C₈H₁₂O₃   | unknown        | —               |
|     | 283.05137     | 283.0612       | 0.606          | negative         |          |         |               |                 |
| 3   | 8.68          | 229.08608      | 229.08592      | 0.702            | positive  | C₁₂H₁₄O₃ | 3,5,4'-trihydroxystilbene | 148.9186        |
|     | 227.07154     | 227.07137      | 0.752          | negative         |          |         |               |                 |
| 4   | 8.68          | 273.07713      | 273.07685      | 1.054            | negative  | C₁₂H₁₄O₅ | 4'-methoxy-3,7-dihydroxyflavan | 115.6472        |
| 5   | 8.72          | 255.06525      | 255.06519      | 0.241            | positive  | C₁₁H₁₀O₄ | 7,4'-dihydroxyflavan | 137.4393        |
|     | 253.05074     | 253.05063      | 0.408          | negative         |          |         |               |                 |
| 6   | 8.74          | 259.09663      | 259.09649      | 0.563            | positive  | C₁₂H₈O₄   | 2,4,4'-Trihydroxydihydrochalcone | 94.5322         |
|     | 257.08211     | 257.08193      | 0.707          | negative         |          |         |               |                 |
| 7   | 8.83          | 314.13891      | 314.13868      | 0.703            | positive  | C₁₁H₁₅O₄ | norisoboldine | 30.448          |
|     | 312.12448     | 312.12413      | 1.11           | negative         |          |         |               |                 |
| 8   | 9.27          | 149.06084      | 149.0608       | 0.219            | negative  | C₉H₁₀O₂   | unknown        | —               |
| 9   | 9.66          | 269.08092      | 269.08193      | 0.594            | negative  | C₁₁H₁₀O₄ | unknown        | —               |
| 10  | 9.78          | 525.19107      | 525.19078      | 0.558            | positive  | C₁₂H₁₀O₇ | dracaemin A | 134.7937        |
|     | 523.1766      | 523.17623      | 0.709          | negative         |          |         |               |                 |
| 11  | 10.02         | 273.11223      | 273.11214      | 0.359            | positive  | C₁₂H₈O₄   | unknown        | —               |
|     | 271.09769     | 271.09758      | 0.385          | negative         |          |         |               |                 |
| 12  | 10.21         | 303.1228       | 303.1227       | 0.339            | positive  | C₁₁H₁₀O₃ | unknown        | —               |
|     | 301.10831     | 301.10815      | 0.331          | negative         |          |         |               |                 |
| 13  | 10.21         | 392.20704      | 392.20676      | 0.696            | positive  | C₁₁H₁₀O₅ | 3,4-O-dimethylcedrusin | 149.4172        |
| 14  | 10.21         | 167.0704       | 167.07027      | 0.788            | positive  | C₉H₁₀O₃   | Ethyl 4-hydroxybenzoate | 216.6625        |
| 15  | 10.57         | 287.09152      | 287.0914       | 0.414            | positive  | C₁₂H₁₀O₅ | unknown        | —               |
|     | 285.0703      | 285.07685      | 0.638          | negative         |          |         |               |                 |
| 16  | 10.73         | 532.23343      | 532.23298      | 0.849            | positive  | C₁₂H₉O₇   | cochincheninin | 21.059          |
|     | 513.19218     | 513.19188      | 0.587          | negative         |          |         |               |                 |
| 17  | 10.95         | 301.10837      | 301.10815      | 0.733            | negative  | C₁₁H₉O₃   | unknown        | —               |
| 18  | 11.2          | 241.08592      | 241.08592      | 0.665            | positive  | C₁₁H₁₀O₃ | (2S)-7-hydroxyflavanone | 227.3156        |
|     | 239.07151     | 239.07137      | 0.616          | negative         |          |         |               |                 |
| 19  | 11.45         | 199.07646      | 199.07645      | 0.057            | negative  | C₁₂H₁₀O₂   | 4,4'-Dihydroxydiphenylmethane | 201.7499        |
| 20  | 11.64         | 529.22251      | 529.22208      | 0.817            | positive  | C₁₂H₉O₇   | unknown        | —               |
|     | 527.20758     | 527.20753      | 0.102          | negative         |          |         |               |                 |
| 21  | 11.65         | 511.21352      | 511.21261      | 1.776            | negative  | C₁₂H₁₀O₅ | homoisosocotrin-4-ol | 17.1673         |
| 22  | 11.86         | 283.09773      | 283.09758      | 0.507            | negative  | C₁₁H₁₀O₄ | unknown        | —               |
| 23  | 12            | 516.23823      | 516.23806      | 0.321            | positive  | C₁₂H₁₀O₄ | socotrin 4-ol | 7.5670          |
| 24  | 12.13         | 287.12781      | 287.12779      | 0.077            | positive  | C₁₁H₁₀O₄ | Loureirin A   | 228.3831        |
| No. | RT (Measured) | m/z (Measured) | m/z (Expected) | m/z (Delta, ppm) | polarity | Formula | Compound Name | Papp (10^{-6} cm/s) |
|-----|--------------|----------------|----------------|------------------|----------|---------|---------------|---------------------|
| 25  | 12.13        | 285.11337      | 285.11323      | 0.492            | negative | C₈H₁₀O₂  | 3,4-Dihydroxy-allylbenzene | 140.4007 |
| 26  | 12.23        | 227.10674      | 227.10666      | 0.351            | positive | C₁₇H₁₇O₂  | 7-hydroxyflavanone         | 227.3156 |
| 27  | 12.23        | 317.13839      | 317.13835      | 0.136            | positive | C₁₈H₂₀O₅  | Loureirin B                | 227.8266 |
|     |              | 315.12406      | 315.1238       | 0.833            | negative |          |               |                     |
| 28  | 12.93        | 257.11728      | 257.11722      | 0.227            | positive | C₁₆H₁₆O₃  | pterostilbene              | 236.2931 |
|     |              | 255.10277      | 255.10267      | 0.396            | negative |          |               |                     |
| 29  | 13           | 885.45033      | 885.44894      | 1.572            | negative | C₄₄H₇₀O₁₈ | 26-O—D-Glucopyranosyl-furostan-5,25(27)-diene-1,3,22,26-tetrol-1-O-[-L-rhamnopyranosyl(12)]—L-Arabinopyranoside | 0.0073 |
| 30  | 13.25        | 167.0704       | 167.07027      | 0.799            | positive | C₈H₁₀O₃  | unknown                 | —                   |
| 31  | 14.08        | 265.14798      | 265.14798      | —                | unknown |          |               |                     |
| 32  | 14.39        | 462.32139      | 462.3214       | —0.029           | positive | C₁₅H₁₆O₅  | dracaenol B              | 141.9713 |
| 33  | 14.90        | 571.23383      | —              | —                | negative |          |               |                     |
| 34  | 14.91        | 527.24323      | 527.24282      | 0.786            | positive | C₁₉H₁₈O₆  | cochinchinenin E          | 8.2809  |
| 35  | 15.77        | 532.92554      | —              | —                | negative |          |               |                     |
| 36  | 15.92        | 325.18451      | 325.18569      | —3.642           | negative | C₁₇H₂₀O₈  | unknown                 | —                   |
| 37  | 16.27        | 415.32104      | 415.32067      | 0.894            | positive | C₂₀H₂₂O₈  | Diosgenin                | 11.23202 |
| 38  | 16.44        | 325.18448      | 325.18569      | —3.734           | negative | C₁₅H₂₀O₈  | unknown                 | —                   |
| 39  | 17.44        | 339.20010      | 339.20134      | —3.668           | negative | C₁₅H₂₀O₈  | unknown                 | —                   |
| 40  | 19.18        | 698.91071      | —              | —                | negative |          |               |                     |
| 41  | 19.95        | 323.25817      | 323.25807      | 0.292            | positive | C₁₉H₂₄O₉  | bincatriol               | 172.7858 |
| 42  | 20.25        | 445.29987      | —              | —                | negative |          |               |                     |
| 43  | 20.49        | 628.19489      | —              | —                | positive |          |               |                     |
| 44  | 20.63        | 383.18988      | 383.19117      | —4.807           | negative | C₁₉H₂₄O₁₀ | unknown                | —                   |
| 45  | 21           | 461.32938      | —              | —                | positive |          |               |                     |
| 46  | 21.6         | 116.92857      | —              | —                | negative |          |               |                     |
| 47  | 22.14        | 394.3465       | 394.34415      | 4.577            | Positive | C₂₅H₄₆O₅ | unknown                 | —                   |
| 48  | 24.99        | 427.3939       | 427.39344      | 1.082            | positive | C₂₁H₃₀O₉  | lupeol                  | 0.0386  |

Papp: apparent permeability coefficient at the indicated concentrations in the basolateral-to-apical (B-A) direction across a Caco-2 cell monolayer.
doi:10.1371/journal.pone.0101432.t001
7.3 Pathway enrichment analysis for the major putative DB targets and the major known therapeutic targets for colitis. We performed pathway enrichment analysis using pathway data obtained from the FTP service of KEGG [43] (Kyoto Encyclopedia of Genes and Genomes, http://www.genome.jp/kegg/, Last updated: Oct 16, 2012).

Results and Discussion

1. Optimization of UPLC-ESI-MS/MS conditions

To obtain reliable chromatographic results and appropriate ionization, four mobile phase systems of acetonitrile-water, methanol-water, acetonitrile-acid aqueous solution, and methanol-acid aqueous solution were tested and compared. The results suggested that acetonitrile-formic acid aqueous solution was superior to the others. Different concentration of formic acid aqueous solution (0.05%, 0.1%, and 0.5%) were investigated,
indicating that use of 0.1% formic acid aqueous solution produced the optimal peak shape and reduced peak tailing, as well as increasing ion response for most compounds. Meanwhile, the process of gradient elution was optimized to obtain better separation over shorter time periods. The MS parameters were optimized to improve ion intensity. These optimized parameters were described in section 2.3. Base peak chromatograms of DB in positive and negative ion modes are shown in Figure 2.

2. Screening and identification of DB using UPLC-ESI-MS/MS

Recently, the UPLC-Q-Exactive system was reported to provide a rapid, reliable and accurate technique for identification of herbal constitutions, because of its separation efficiency, high resolution and high mass accuracy [44–46]. In the present study, a total of 48 components of DB were identified. These were mainly flavonoids, such as flavones, flavonols, flavanones, chalcones, and isoflavones, as listed in Table 1. For some compounds (7,4’-dihydroxyflavan, loureirin A, loureirin B, pterostilbene, and dracaenin A), purified standards were available and these were identified by comparing sample retention time and accurate mass with that of the standard. For compounds where standards were unavailable, identification was based on accurate mass and tandem mass spectra. The molecular formula was established by high-accuracy quasi-molecular ion such as [M-H]−, [M+CH3COO]−, [M+H]+, and [M+Na]+ within a mass error of 5.0 ppm and fractional isotope abundance. The most rational molecular formula was identified using chemical or herbal databases, such as Chemsperider (www.

Figure 4. The MS/MS spectrum and possible fragmentation pathways of 7,4’-dihydroxyflavan. doi:10.1371/journal.pone.0101432.g004
When several isomers were matched, a compound that had previously been identified in DB was considered more likely to be correct. Finally, ion fragments were used to provide further confirmation of the chemical structure. The structures of the main constituents of DB are shown in Figure 3. For example, 7,4,9-dihydroxyflavan (compound 5) was firstly identified by comparing its retention time and accurate mass with that of the appropriate standard. Then, the MS/MS spectrum and possible fragmentation pathways of 7,4,9-dihydroxyflavan were depicted in Figure 4. Only [M+H]+ and [M–H]2 were observed in positive and negative ion modes, respectively. The loss of 128 Da and 136 Da were the characteristic neutral loss of 7,4,9-dihydroxyflavan in positive and negative ion modes.

3. Prediction of absorbed DB constituents and their metabolites by in silico ADME models

Quantitative structure-permeability relationships (QSPerR) have been established for permeability across Caco-2 monolayers (Papp) by the application of new molecular descriptors [47]. Among them, the passive Caco-2 absorption model provides a useful drug discovery tool by predicting human oral absorption of new chemical entities [48–49]. Yazdanian et al. [50] reported that compounds with Papp values less than 0.4 × 10⁻⁶ cm/s exhibited very poor oral absorption, whereas compounds with Papp values of 1.0 × 10⁻¹ cm/s were considered to be highly absorbed.

| No. | Compound name                  | Score | Reliability | Reaction site | Reaction type                  | Metabolizing enzymes |
|-----|--------------------------------|-------|-------------|---------------|--------------------------------|----------------------|
| M1  | 3,5,4'-trihydroxy-Stilbene     | 0.94  | 0.86        | 3             | Aromatic Hydroxylation         | CYP1A2               |
| M2  | 3,5,4'-trihydroxy-Stilbene     | 0.94  | 0.86        | 7             | Aromatic Hydroxylation         | CYP1A2               |
| M3  | 4'-methoxy-3',7'-dihydroxyflavan | 0.92  | 0.78        | 14            | Aromatic Hydroxylation         | CYP1A2               |
| M4  | 3',4'-Dihydroxyflavan         | 0.92  | 0.79        | 13            | Aromatic Hydroxylation         | CYP1A2               |
| M5  | 3,4-Dihydroxy-allylbenezene   | 0.85  | 0.74        | 4             | Aliphatic Hydroxylation        | CYP1A2               |
| M6  | 3,4-Dihydroxy-allylbenezene   | 0.91  | 0.86        | 4             | Aliphatic Hydroxylation        | CYP1A2               |
| M7  | Lourein B                     | 0.74  | 0.5         | 18            | Aromatic Hydroxylation         | CYP1A2               |
| M8  | Lourein B                     | 0.74  | 0.5         | 19            | Aromatic Hydroxylation         | CYP1A2               |
| M9  | 4'-methoxy-3',7'-dihydroxyflavan | 0.92  | 0.79        | 21            | O-dealkylation                  | CYP1A2               |
| M10 | 3',4'-Dihydroxyflavan         | 0.92  | 0.79        | 13            | Aromatic Hydroxylation         | CYP1A2               |
| M11 | 3,4-Dihydroxy-allylbenezene   | 0.85  | 0.74        | 4             | Aliphatic Hydroxylation        | CYP1A2               |
| M12 | 3,4-Dihydroxy-allylbenezene   | 0.91  | 0.86        | 4             | Aliphatic Hydroxylation        | CYP1A2               |

Figure 5. DB chemical component-putative target network. Blue squares refer to the DB compounds and metabolites; yellow spherical nodes refer to the predicted targets. doi:10.1371/journal.pone.0101432.g005

chemspider.com) and TCM Database@Taiwan (http://tcm.cmu.edu.tw). When several isomers were matched, a compound that had previously been identified in DB was considered more likely to be correct. Finally, ion fragments were used to provide further confirmation of the chemical structure. The structures of the main constituents of DB are shown in Figure 3. For example, 7,4,9-dihydroxyflavan (compound 5) was firstly identified by comparing its retention time and accurate mass with that of the appropriate standard. Then, the MS/MS spectrum and possible fragmentation pathways of 7,4,9-dihydroxyflavan were depicted in Figure 4. Only [M+H]+ and [M–H]2 were observed in positive and negative ion modes, respectively. The loss of 128 Da and 136 Da were the characteristic neutral loss of 7,4,9-dihydroxyflavan in positive and negative ion modes.
greater than $7 \times 10^{-6}$ cm/s had excellent oral absorption. The present study employed an *in silico* passive Caco-2 absorption model within the ACD/Percepta software to identify DB constituents with excellent oral absorption values (greater than $7 \times 10^{-6}$ cm/s) and the results were shown in Table 1. Subsequently, the ACD/Percepta software P450 regioselectivity module was applied to predict the metabolites of these well-absorbed DB constituents. These results were listed in Table 2 and the structures of the metabolites were shown in Figure 3.

4. Analysis of DB pharmacological mechanisms in colitis

In order to analyze the synergistic effects and pharmacological mechanisms of DB in colitis, we constructed a chemical component-putative target network, and a putative DB targets-known colitis therapeutic targets PPI network. Detailed information relating to these similar drugs and putative targets is provided in supplementary Table S3. The performance of this prediction method was evaluated in our previous study [34].

4.1. DB chemical component-putative target network.
As shown in Figure 5, this network consisted of 67 nodes (15 absorbed components, 4 metabolites and 48 putative targets) and 120 edges. The mean number of putative targets per chemical component/metabolite was 2.53. The absorbed DB component 14 and the metabolite M5 of compound 25 (3,4-dihydroxy-allylbenzene) both had the highest degree distributions, and hit 23 and 14 putative targets, respectively. Since chemical components or metabolites with a higher degree in the network have been demonstrated to be more pharmacologically important, and our data indicated that components 25, 32, and the M5 metabolite had the shortest paths between each other, they may play major roles in this pharmacological network, with synergistic effects.

4.2. Putative DB targets-known colitis therapeutic targets PPI network.
Putative DB targets-known colitis therapeutic targets PPI network was constructed using PPIs between putative DB targets and known colitis therapeutic targets. As shown in Figure 6A, this network consisted of 2397 nodes and 4005 edges. According to the previous study of Li et al. [51], if the degree of a node is more than 2 fold of the median degree of all nodes in a network, such node is believed to play a critical role in the network structure, and can be treated as a hub node. Thus, we identified 463 hub proteins. Then, the PPI network of these hub proteins was constructed using the direct PPIs between them. As a result, this network consisted of 463 nodes and 1574 edges (Figure 6B). In addition, we calculated four topological feature values of all 463 nodes in the PPI network of hub proteins according to the definition described in section 2.7.2. We defined a hub protein, the four topological feature values of which were all larger than the corresponding median values, as a major hub protein. After the calculation, the median values of the four topological features were 5, 0.06, 31.30, and 3 for “degree,” “betweenness,” “closeness,” and “k value,” respectively. Therefore, we determined that hub proteins with “degree” $>3$, “betweenness” $>0.06$, “closeness” $>31.30$, and “k value” $>3$ were major hubs. As a result, 106 proteins were identified as major hubs, including 18 putative DB targets and 16 known therapeutic targets for colitis. Detailed information on the topological features of these major hubs is provided in supplementary Table S4.

To investigate the pharmacological mechanisms of DB in colitis further, we analyzed the direct PPIs between the major putative DB targets and the major known therapeutic targets for colitis. As shown in Figure 6C, this network contained 34 nodes and 42 edges. According to the results of enrichment analysis based on the KEGG pathway [43], these major target proteins were frequently involved in the NOD-like receptor signaling pathway (KEGG ID: map04621). The intracellular NOD-like receptor (NLR) family contains more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. NOD1 and NOD2, two prototypic NLRs, sense the cytosolic presence of bacterial peptidoglycan fragments that have escaped from endosomal compartments, driving the activation of NF-kappa-B and MAPK, cytokine production, and apoptosis [52]. Accumulating studies have demonstrated that several members of the NOD-like receptor signaling pathway, such as heat shock protein 90 (Hsp90) [53], interleukin-6 (IL-6) [54], tumor necrosis factor alpha (TNF-$\alpha$) [55], NF-kappa-B inhibitor kinase alpha (IKKA) [56], IKKB [56], and adrenergic receptors [57], may be associated with the pathogenesis of colitis. Of these proteins, Hsp90, ADRB1, and ADRB2 were identified as putative DB targets. Moreover, a number of putative DB targets also interacted with members of the NOD-like receptor signaling pathway, as shown in Fig. 6C. These findings suggested that the therapeutic effects of DB on colitis may involve this pathway.

**Conclusion**

High-throughput analysis, *in silico* ADME prediction, and network pharmacology techniques have recently emerged as powerful tools to provide new insights into the active compounds.
and the molecular mechanisms involved in the therapeutic actions of traditional Chinese medicines. In this study, a rapid, sensitive, and high-throughput analytical method using UPLC-ESI-MS/MS was firstly developed to characterize 48 constituents and accurately identify 24 constituents of DB tablet. Then, 22 components of DB tablet were predicted to be absorbed by an in silico passive absorption model, based on the Caco-2 cell monolayer. Eight metabolites were predicted using a computational module of P450 regioselectivity. Finally, these compounds were predicted to interact with 26 putative targets. Using this information, pharmacological networks were built to visualize the synergistic interactions between DB components and their targets. Furthermore, a PPI network of putative DB targets and known therapeutic targets for colitis was constructed to pinpoint the key targets and pathways. This approach offered a valuable opportunity to deepen understanding of the pharmacological mechanisms of DB in colitis.

In summary, this research provided a more accurate analysis of DB constituents, compared to using TCM databases. Consideration of ADME using the passive absorption and P450 metabolism modules in silico predicted the in vivo situation more closely. Finally, network pharmacology analysis was applied effectively and helped to interpret the essence of “synergy” in Chinese medicine. This provided a new way to identify the key candidate targets and possible molecular pathways utilized by DB in the treatment of colitis.

**Supporting Information**

| Table S1 | The detailed target information for colitis. |
|---------|------------------------------------------|
| Table S2 | The detailed PPI information of colitis based on eight existing PPI databases. |
| Table S3 | Detailed information relating to these similar drugs and putative targets for DB curing colitis. |

**Table S4** Detailed information on the topological features of these major hubs including 18 putative DB targets and 16 known therapeutic targets for colitis.

**Author Contributions**

Conceived and designed the experiments: XG GZ HY LH. Performed the experiments: HX Yanqiong Z, YL HZ RL DL. Yi Z. Analyzed the data: NL ST. Contributed to the writing of the manuscript: YM.

**References**

1. Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complementary and alternative medicine use among adults: United States, 2002. Adv Data 27:1–19.
2. US Food and Drug Administration (2006) Guidance for industry on complementary and alternative medicine products and their regulation by the Food and Drug Administration.
3. Xu H, Tao Y, Lu P, Wang P, Zhang F, et al. (2013) A computational drug-target network for yuha zhitong prescription. Evid Based Complement Alternat Med e650531: 1–15.
4. Zhang B, Wang X, Li S (2013) An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Lao-Yin. Evid Based Complement Alternat Med e546747: 1–12.
5. Zhang GB, Li QY, Chen QL, Su SB (2013) Network Pharmacology: A New Approach for Chinese Herbal Medicine Research. Evid Based Complement Alternat Med e621823: 1–9.
6. Chen CY (2011) TCM database Taiwan: the world's largest traditional Chinese medicine database for drug screening In Silico. PLoS ONE 6(1): e15939.
7. Li S, Zhang B, Yuan J (2011) A HerbBioMap database. China Copyright of Computer Software, 2011SR076302.
8. Tao Y, Xu H, Wang S, Wang B, Zhang Y, et al. (2013) Identification of the absorbed constituents after oral administration of Yuha Zhitong prescription extract and its pharmacokinetic study by rapid resolution liquid chromatography/mass spectrometry time-of-flight. J Chromatogr A Analytical Biomed Life Sci 953:1–9.
9. Xu H, Li K, Chen Y, Zhang Y, Tang S, et al. (2013) Study on the absorbed fingerprint-efficacy of Yuha Zhitong tablet based on chemical analysis, vaporolization evaluation and data mining. PLoS One 8(12): e81135.
10. Arrtunson P, Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficient in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175: 880–885.
11. U.S. Department of Health and Human Services, FDA (2000) Center for Drug Evaluation and Research. Guidance for Industry on Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on In Vitro Methods. 2000: 28–40.
12. Marrero Ponce Y, Cabrera Pérez MA, Romero Zaldivar V, González Díaz H, Torrents F (2004) A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture. J Pharm Pharm Sci 7(2):186–99.
13.State Pharmacopoeia Committee (2010) Pharmacopoeia of the People’s republic of china. Beijing: China Medical Science and Technology Press 173.
14. The Editorial Committee (1999) Materia medica of china (volume 8). Shanghai: Shanghai Science and Technology Publishing House 455.
15. Zhu ZY (2012) Nursing experience of lungxueji combined with levofloxacin retention enema in treating ulcerative colitis. J Clin Med Pract 16: 47–49.
16. Hu WB, Gao SH, Gao YL (2011) Treating 40 Cases of Chronic Colitis by Lungxueji plus Western Medicine. J Prac Trad Chin Med 25: 56–57.
17. Feng SH, Liu B, Du R, Sun J (2011) Clinical Observation of Choroidal Neovascularization Treated with Herbal Medicine Lungxueji Tablets. World J Integr Trad Med 6: 496–498.
18. Arnone A, Nasini G, Merlini L (1990) Constituents of dragon’s blood. Part 4. Dracoffavan a, a novel secoiridoid flavonoid. J Chem Soc Perkin 10: 2637–2649.
19. Chen CC, Tsai NY, Wei SL, Wang ST, Sheh BJ, et al. (2007) Flavonoids isolated from dracaena resina. Nat Prod Res 21: 377–380.
20. Pozzi F, Passannanti S, Paternostro MP, Nasini G (1974) Diterpenoid resin acids of daemorons Draco. Phytochemistry 13: 2251–2253.
21. Nasini G, Pozzi F (1981) Pterocarpos and triterpenes from daemorons Draco. Phytochemistry 20: 514–516.
22. Shi J, Hu R, Lu Y, Sun C, Wu T (2009) Single-step purification of dracorhodin from dragon’s blood resin of Daemorons Draco using high-speed counter-current chromatography combined with pH modulation. J Sep Sci 32: 4040–4047.
23. De Marino S, Gala F, Zollo F, Vitalini S, Fico G, et al. (2008) Identification of minor secondary metabolites from the latex of Croton lechleri (Muel-Arg) and evaluation of their antioxidant activity. Molecules 13:1219–1229.
24. Baumer U, Dieteman P (2010) Identification and differentiation of dragon’s blood in works of art using gas chromatography/mass spectrometry. Anal Bioanal Chem 397:1363–76.
25. Yi T, Yang T, Zhang J, Zhao Z, Yang Z, et al. (2012) Characterization and determination of six flavonoids in the ethnomedicine “Dragon’s Blood” by UPLC-PAD-MS. Chem Cent J 6: 116.
26. Milburn M (1984) Dragon’s Blood in East & West Africa, Arabia and the Canary Islands. Africa 39: 490–493.
27. Badib AS (1991) Medicinal plants of the Yemen Maltalrah Alnaiad: Sanaa 15.
28. Wangensteen H, Klarpa˚s L, Alamgir M, Samuelsen ABC, Malterud KE (2013) Dracaena Draco and other species of Dracaena: Drug discovery and alternative medicine use among adults: United States, 2002. Adv Data 27:1–19.
29. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, et al. (2010) The Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 38: D901–D906.
30. Chen Y, Mandipalli SR, Yuan TX (2009) HAPPI: an online database of comprehensive human annotated and predicted protein interactions. BMC Genomics (Suppl 1): S16.
31. Matsi M, Gospinath G, Gillespie M, Caudy M, Croft D, et al. (2009) Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 37: D619–622.
32. Brown KR, Jurisica I (2005) Online predicted human interaction database. Bioinformatics 21: 2076–2082.
33. Aranda B, Achuthan P, Alam-Faruque Y, Armean I, Bridge A, et al. (2010) The IntAct molecular interaction database in 2010. Nucleic Acids Res 38: D525–D531.
34. Krishna Prasad TS, Goel R, Kandassamy K, Kervihrkanam S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767–D772.
35. Coel A, Charr Aryamonti A, Lecata I, Pheluso D, Briganti L, et al. (2010) MINT, the molecular interaction database: 2009 update. Nucleic Acids Res 38: D532–D539.
36. Lehne B, Schlütt T (2009) Protein-protein interaction databases: keeping up with growing interactomes. Hum. Genomics 5: 291–297.
37. Brüning T, Skrabanek I, Niu MY, Mukherjee P, Weinstein H (2005) PDZBase: a protein-protein interaction database for PDZ-domains. Bioinformatics 21: 827–828.
38. Zhang Y, Wang D, Tan S, Xu H, Liu C, et al. (2013) A systems biology-based investigation into the pharmacological mechanisms of Wu Tou Tang acting on rheumatoid arthritis by integrating network analysis. Evid Based Complement Alternat Med e548498: 1–12.
39. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1129–D1136.
40. Wang Y1, Liu Z, Li C, Li D, Ouyang Y, et al (2012) Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease. Evid. Based Complement Altern. Med. 2012: 698531.
41. Azuaje FJ, Zhang L, Devaux Y, Wagner DR (2011) Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs. Scientific Reports 1: 1–10.
42. Wuchty S, Almaas E (2005) Evolutionary cores of domain co-occurrence networks. BMC Evol Biol 5: 24.
43. Wixon J, Kell D (2000) The Kyoto encyclopedia of genes and genomes—KEGG. Yeast 17: 48–55.
44. Guillemard D, Schappler J, Rudaz S, Veuthey JL (2010) Coupling ultra-high-pressure liquid chromatography with mass spectrometry. TrAC Trends Anal Chem 29:15–27.
45. Theodoridis GA, Gika HG, Want EJ, Wilson ID (2012) Liquid chromatography-mass spectrometry based global metabolite profiling: a review. Anal Chim Acta 711: 7–16.
46. Michalski A, Damoc E, Hauschild JP, Lange O, Wieghaus A, et al. (2011) Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer. Mol Cell Proteomics 10: M111.011015.
47. Yovani Marrero P, Miguel Angel C, Vicente Romero Z, Ernest O, Luis AM (2003) Total and local quadratic indices of the “molecular pseudograph’s atom adjacency matrix”. Application to prediction of Caco-2 permeability of drugs. Int. J Mol Sci 4: 512–536.
48. Zhang J, Zhang Y, Zhang S, Wang S, He L (2010) Discovery of novel taspine derivatives as antiangiogenic agents. Bioorg Med Chem Lett 20: 718–721.
49. Zhou L, Chow MS, Zuo Z (2009) Effect of sodium caprate on the oral absorptions of danhensu and salvianolic acid B. Int J Pharm 375:109–118.
50. Yazdanian M, Glynn SL, Wright JL, Hawi A (1998) Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. Pharm Res 15: 1490–1494.
51. Li S, Zhang QZ, Wu LJ, Zhang XG, Li YD, et al. (2007) Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. EIT Syst Biol 1: 51–60.
52. Rubino SJ, Selvanantham T, Girardin SE, Philpott DJ (2012) Nod-like receptors in the control of intestinal inflammation. Curr Opin Immunol 24: 398–404.
53. Tomasello G, Sciamé C, Rappa F, Rodolico V, Zerilli M, et al. (2011) Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy. Eur J Histochem 55: e30.
54. Wine E, Mack DR, Hyams J, Olej AR, Markowitz J, et al. (2013) Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. J Crohns Colitis 7: 916–922.
55. Lv R, Qiao W, Wu Z, Wang Y, Dai S, et al. (2014) Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One 9: e86692.
56. Horwitz B (2005) NF-kappa B, an inhibitor of microflora-induced colitis. J Pediatr Gastroenterol Nutr 40 (Suppl 1): S22–3.
57. Sikander A, Rana SV, Sharma SK, Sinha SK, Arora SK, et al. (2010) Association of alpha 2A adrenergic receptor gene (ADRA2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis. Clin Chim Acta 411: 59–63.